Sage Therapeutics, Inc
SAGE Real Time Price USDRecent trades of SAGE by members of U.S. Congress
| Politician | Type | Traded |
|---|---|---|
| Ro Khanna House / D | Purchase $1,001 - $15,000 | Nov 03, 2020 |
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by SAGE's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
-
$50,000 Apr 18, 2025 Issue: Health Issues
-
$170,000 Jan 10, 2025 Issue: Health Issues Medicare/Medicaid Budget/Appropriations
-
$120,000 Oct 18, 2024 Issue: Medicare/Medicaid Health Issues
-
$140,000 Jul 19, 2024 Issue: Medicare/Medicaid Health Issues
-
$140,000 Apr 22, 2024 Issue: Medicare/Medicaid Health Issues
-
$110,000 Jan 19, 2024 Issue: Medicare/Medicaid Health Issues
-
$140,000 Oct 18, 2023 Issue: Medicare/Medicaid Health Issues
-
$130,000 Jul 19, 2023 Issue: Medicare/Medicaid Health Issues
-
$110,000 Jan 19, 2023 Issue: Medicare/Medicaid Health Issues
-
$120,000 Oct 20, 2022 Issue: Medicare/Medicaid Health Issues
-
$284,000 Oct 19, 2022 Issue: Medicare/Medicaid Health Issues
-
$197,756 Apr 19, 2022 Issue: Medicare/Medicaid Health Issues
-
$197,756 Jan 20, 2022 Issue: None
-
$275,000 Oct 22, 2021 Issue: None
-
$275,000 Jul 20, 2021 Issue: None
-
$287,000 Apr 20, 2021 Issue: None
-
$223,000 Jan 20, 2021 Issue: None
-
$287,000 Oct 19, 2020 Issue: None
-
$166,315 Jul 20, 2020 Issue: HEALTH ISSUES
-
$218,437 Apr 22, 2020 Issue: HEALTH ISSUES
-
$229,013 Jan 21, 2020 Issue: HEALTH ISSUES
-
$206,000 Oct 21, 2019 Issue: Health Issues
-
$154,000 Jul 22, 2019 Issue: Health Issues Copyright/Patent/Trademark
-
$50,000 Apr 22, 2019 Issue: Health Issues
-
$50,000 Jan 22, 2019 Issue: Health Issues
-
$50,000 Oct 16, 2018 Issue: Health Issues
-
$50,000 Jul 20, 2018 Issue: Health Issues
-
$30,000 Apr 19, 2018 Issue: Health Issues
-
$10,000 Oct 17, 2012 Issue: Defense Medical/Disease Research/Clinical Labs
-
$30,000 Jul 12, 2012 Issue: Medical/Disease Research/Clinical Labs Defense
-
$30,000 Apr 16, 2012 Issue: Medical/Disease Research/Clinical Labs Defense
-
$30,000 Jan 10, 2012 Issue: Medical/Disease Research/Clinical Labs Defense
-
$30,000 Oct 12, 2011 Issue: Defense Medical/Disease Research/Clinical Labs
-
$30,000 Jul 16, 2011 Issue: Defense Medical/Disease Research/Clinical Labs
-
$20,000 Apr 18, 2011 Issue: Medical/Disease Research/Clinical Labs Defense
Estimated quarterly lobbying spending
SAGE Revenue by Segment or Geography
New patents grants
-
Patent Title: Oxysterols and methods of use thereof Apr. 08, 2025
-
Patent Title: Neuroactive steroids and their methods of use Apr. 01, 2025
-
Patent Title: Neuroactive steroids and their methods of use Mar. 18, 2025
-
Patent Title: 19-nor c3,3-disubstituted c21-n-pyrazolyl steroids and methods of use thereof Jan. 21, 2025
-
Patent Title: Compositions and methods for treating cns disorders Dec. 31, 2024
-
Patent Title: Oxysterols and methods of use thereof Dec. 31, 2024
-
Patent Title: Oxysterols and methods of use thereof Oct. 29, 2024
-
Patent Title: Neuroactive steroids, compositions, and uses thereof Oct. 29, 2024
-
Patent Title: Crystalline forms of a neuroactive steroid Oct. 22, 2024
-
Patent Title: Neuroactive steroids, compositions, and uses thereof Sep. 10, 2024
-
Patent Title: Neuroactive steroids, compositions, and uses thereof Aug. 27, 2024
-
Patent Title: Compositions and methods for treating cns disorders Aug. 20, 2024
-
Patent Title: Compositions and methods for treating cns disorders Aug. 13, 2024
-
Patent Title: Methods of treating epilepsy or status epilepticus Jul. 30, 2024
-
Patent Title: Neuroactive steroids and their methods of use Jun. 04, 2024
-
Patent Title: C7, c12, and c16 substituted neuroactive steroids and their methods of use May. 28, 2024
-
Patent Title: Neuroactive steroids and their methods of use Apr. 30, 2024
-
Patent Title: Crystalline forms of a neuroactive steroid Apr. 09, 2024
-
Patent Title: Compositions and methods for treating cns disorders Apr. 02, 2024
-
Patent Title: C7 substituted oxysterols and methods of use thereof Mar. 12, 2024
-
Patent Title: Neuroactive steroids and their methods of use Feb. 27, 2024
-
Patent Title: Neuroactive steroids and methods of use thereof Feb. 20, 2024
-
Patent Title: Oxysterols and methods of use thereof Jan. 30, 2024
-
Patent Title: Crystalline 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid Jan. 30, 2024
-
Patent Title: Oxysterols and methods of use thereof Jan. 23, 2024
-
Patent Title: Oxysterols and methods of use thereof Dec. 26, 2023
-
Patent Title: Neuroactive steroids, compositions, and uses thereof Oct. 10, 2023
-
Patent Title: Oxysterols and methods of use thereof Aug. 22, 2023
-
Patent Title: Compositions and methods for treating cns disorders Aug. 08, 2023
-
Patent Title: Compositions and methods for treating cns disorders Jun. 06, 2023
-
Patent Title: Neuroactive steroids and compositions thereof May. 09, 2023
-
Patent Title: Neuroactive steroids substituted in position 10 with a cyclic group for use in the treatment of cns disorders Apr. 25, 2023
-
Patent Title: Oxysterols and methods of use thereof Mar. 28, 2023
-
Patent Title: Neuroactive steroids, compositions, and uses thereof Jan. 17, 2023
-
Patent Title: Compositions and methods for treating cns disorders Jan. 03, 2023
-
Patent Title: Compositions and methods for treating cns disorders Dec. 20, 2022
-
Patent Title: Neuroactive steroids, compositions, and uses thereof Nov. 15, 2022
-
Patent Title: Neuroactive steroid formulations and methods of treating cns disorders Aug. 30, 2022
-
Patent Title: Oxysterols and methods of use thereof Aug. 09, 2022
-
Patent Title: C17, c20, and c21 substituted neuroactive steroids and their methods of use Jul. 26, 2022
-
Patent Title: 19-nor c3, 3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof May. 31, 2022
-
Patent Title: Oxysterols and methods of use thereof Mar. 22, 2022
-
Patent Title: 19-nor neuroactive steroids and methods of use thereof Mar. 01, 2022
-
Patent Title: 19-nor c3, 3-disubstituted c21-n-pyrazolyl steroids and methods of use thereof Feb. 08, 2022
-
Patent Title: Crystalline 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid Feb. 01, 2022
-
Patent Title: Neuroactive steroids, compositions, and uses thereof Oct. 19, 2021
-
Patent Title: C7 substituted oxysterols and methods of use thereof Oct. 19, 2021
-
Patent Title: Oxysterols and methods of use thereof Oct. 19, 2021
-
Patent Title: Compositions and methods for treating cns disorders Oct. 19, 2021
-
Patent Title: Neuroactive steroids, compositions, and uses thereof Sep. 21, 2021
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Recent insights relating to SAGE
Recent picks made for SAGE stock on CNBC
ETFs with the largest estimated holdings in SAGE
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $SAGE stock a Buy, Sell, or Hold?
- What is the price target for $SAGE stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $SAGE stock?
- Who owns the most shares of $SAGE stock?
- What funds own $SAGE stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view SAGE Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.